Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : PLRX exchanges : Nasdaq save search
Cough in Idiopathic Pulmonary Fibrosis Therapeutics Market to Exhibit Immense Growth at a CAGR of 4.9% by 2034 | DelveInsight
Published: 2024-04-03 (Crawled : 22:00) - prnewswire.com
PLRX | $12.86 -3.02% -3.11% 270K
|
Health Technology
|
| O: 1.87%
H: 3.4%
C: -1.02%
fibrosis therapeutics growth market
Pliant Therapeutics to Participate in Upcoming Investor Events
Published: 2024-04-02 (Crawled : 12:00) - globenewswire.com
PLRX | $12.86 -3.02% -3.11% 270K
|
Health Technology
|
| O: -0.62%
H: 1.17%
C: 1.17%
therapeutics
Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference
Published: 2024-03-27 (Crawled : 14:30) - globenewswire.com
PLRX | $12.86 -3.02% -3.11% 270K
|
Health Technology
|
| O: 1.34%
H: 3.63%
C: 1.54%
conference international therapeutics
Nimbus Therapeutics Appoints Katharine Knobil, M.D., to Board of Directors
Published: 2024-03-12 (Crawled : 17:00) - biospace.com/
PLRX | $12.86 -3.02% -3.11% 270K
|
Health Technology
|
| O: 0.0%
H: 6.88%
C: 4.2%
MRKR | $4.4 0.23% 11K
|
Consumer Services
|
| O: -1.2%
H: 4.88%
C: 3.17%
therapeutics
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
Published: 2024-03-12 (Crawled : 12:00) - globenewswire.com
PLRX | $12.86 -3.02% -3.11% 270K
|
Health Technology
|
| O: 0.0%
H: 6.88%
C: 4.2%
treatment fibrosis bexotegrast therapeutics
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results
Published: 2024-02-27 (Crawled : 21:00) - globenewswire.com
PLRX | $12.86 -3.02% -3.11% 270K
|
Health Technology
|
| O: 4.59%
H: 0.0%
C: -7.67%
update therapeutics financial results
Pliant Therapeutics to Participate in Upcoming Investor Conferences
Published: 2024-02-26 (Crawled : 13:00) - globenewswire.com
PLRX | $12.86 -3.02% -3.11% 270K
|
Health Technology
|
| O: -0.3%
H: 4.27%
C: 1.4%
therapeutics
Pliant Therapeutics to Participate in Upcoming Investor Events - February 7, 2024
Published: 2024-02-07 (Crawled : 15:00) - biospace.com/
PLRX | $12.86 -3.02% -3.11% 270K
|
Health Technology
|
| O: 0.0%
H: 0.93%
C: -0.87%
therapeutics
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
Published: 2024-02-04 (Crawled : 00:00) - globenewswire.com
PLRX | $12.86 -3.02% -3.11% 270K
|
Health Technology
|
| O: -3.62%
H: 0.0%
C: -5.78%
liver positive fibrosis bexotegrast trial therapeutics
Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Published: 2024-01-03 (Crawled : 13:00) - globenewswire.com
PLRX | $12.86 -3.02% -3.11% 270K
|
Health Technology
|
| O: 0.28%
H: 3.44%
C: 0.28%
conference therapeutics
Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis
Published: 2023-11-13 (Crawled : 22:00) - globenewswire.com
PLRX | $12.86 -3.02% -3.11% 270K
|
Health Technology
|
| O: 4.05%
H: 0.6%
C: -1.5%
meeting liver therapeutics
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
Published: 2023-11-09 (Crawled : 21:00) - globenewswire.com
PLRX | $12.86 -3.02% -3.11% 270K
|
Health Technology
|
| O: 10.0%
H: 2.94%
C: -11.46%
update therapeutics financial results
Pliant Therapeutics to Participate in Upcoming Investor Conferences
Published: 2023-11-08 (Crawled : 13:00) - globenewswire.com
PLRX | $12.86 -3.02% -3.11% 270K
|
Health Technology
|
| O: 0.76%
H: 0.0%
C: -4.93%
therapeutics
Pliant Therapeutics Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer Highlight PLN-101095, A Novel Inhibitor of Integrins αvβ8 and αvβ1
Published: 2023-11-06 (Crawled : 13:00) - globenewswire.com
PLRX | $12.86 -3.02% -3.11% 270K
|
Health Technology
|
| O: -0.12%
H: 1.37%
C: -3.98%
pln-1010 cancer immunotherapy meeting therapeutics
Primary Sclerosing Cholangitis Market to Grow at a Tremendous CAGR of 17.2% During the Study Period (2019-2032) | DelveInsight
Published: 2023-10-31 (Crawled : 21:00) - prnewswire.com
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: 0.94%
H: 2.55%
C: 2.55%
ALPMY | News | $9.34 -1.11% 690K
|
Manufacturing
|
| O: -4.18%
H: 0.49%
C: -0.02%
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -2.76%
H: 0.0%
C: 0.0%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: 0.0%
PLRX | $12.86 -3.02% -3.11% 270K
|
Health Technology
|
| O: -0.2%
H: 3.45%
C: 1.37%
CALT | $18.8 5.62% 5.32% 6.8K
|
Health Technology
|
| O: -2.27%
H: 2.01%
C: 0.44%
study market
Pliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer
Published: 2023-10-31 (Crawled : 20:00) - globenewswire.com
PLRX | $12.86 -3.02% -3.11% 270K
|
Health Technology
|
| O: -0.2%
H: 3.45%
C: 1.37%
cancer immunotherapy meeting therapeutics
Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023
Published: 2023-10-19 (Crawled : 12:00) - globenewswire.com
PLRX | $12.86 -3.02% -3.11% 270K
|
Health Technology
|
| O: -0.3%
H: 3.26%
C: 2.74%
meeting liver presentation bexotegrast therapeutics
Pliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer
Published: 2023-10-16 (Crawled : 20:00) - globenewswire.com
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: -0.4%
H: 0.0%
C: 0.0%
PLRX | $12.86 -3.02% -3.11% 270K
|
Health Technology
|
| O: -0.78%
H: 2.85%
C: -3.27%
therapeutics
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
Published: 2023-09-26 (Crawled : 12:00) - globenewswire.com
ARVL | News | $0.49 0.37% 2.5M
|
Manufacturing
|
| O: -1.24%
H: 0.0%
C: 0.0%
PLRX | $12.86 -3.02% -3.11% 270K
|
Health Technology
|
| O: 7.89%
H: 11.25%
C: 5.98%
liver positive fibrosis bexotegrast trial therapeutics
Pliant Therapeutics to Host Investor Call and Webcast to Discuss Interim Results from INTEGRIS-PSC, a Phase 2a Trial in Patients with Primary Sclerosing Cholangitis
Published: 2023-09-25 (Crawled : 20:00) - globenewswire.com
PLRX | $12.86 -3.02% -3.11% 270K
|
Health Technology
|
| O: 7.89%
H: 11.25%
C: 5.98%
trial therapeutics
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.